文献速递糖尿病

四跨膜蛋白7自身抗体可预测LADA患者β细胞功能进行性下降

Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA.
PubMed 文献 · Diabetologia · 2018-12-29

该研究在横断面队列(LADA 173例、1型糖尿病158例、2型糖尿病204例、健康对照170例)和纵向队列(LADA 53例,随访3年)中评估TSPAN7A对LADA患者β细胞功能的预测价值。结果显示TSPAN7A在LADA中阳性率为21.4%,且阳性者空腹及餐后C肽年下降率显著高于阴性者,提示TSPAN7A是预测LADA β细胞功能下降的有效抗体。

要点

  • TSPAN7A在LADA中阳性率21.4%,可增加多抗体阳性检出率。
  • TSPAN7A阳性者空腹及餐后C肽年下降率显著高于阴性者。
  • TSPAN7A阳性、病程及GAD抗体滴度是β细胞功能风险因素。

核心结论

  • TSPAN7A是东亚自身免疫性糖尿病人群中有效的胰岛自身抗体,可区分LADA患者中疾病进展后β细胞功能较低者。

研究设计与样本

  • 横断面研究纳入LADA 173例、1型糖尿病158例、2型糖尿病204例及健康对照170例。
  • 纵向研究纳入53例LADA患者,随访3年。
  • 采用荧光素酶免疫沉淀系统测定血清TSPAN7A,并记录临床特征。

主要发现

  • TSPAN7A在LADA、1型糖尿病、2型糖尿病和健康对照中的阳性率分别为21.4%(37/173)、26%(41/158)、0.5%(1/204)和1.2%(2/170)。
  • 检测TSPAN7A使LADA中多抗体阳性者比例从22%显著增加至32.4%(p < 0.001)。
  • 逻辑回归显示TSPAN7A阳性(OR 2.87,p = 0.034)、病程(OR 1.83,p = 0.019)和GAD抗体滴度(OR 2.67,p = 0.009)是LADA β细胞功能的危险因素,BMI(OR 0.34,p = 0.001)为保护因素。
  • 在LADA前瞻性研究中,TSPAN7A阳性者空腹C肽和餐后2小时C肽的年下降率中位数分别为34.6%和33.2%,显著高于阴性者的7.9%(p = 0.043)和11%(p = 0.041)。

临床怎么用

  • 可考虑检测TSPAN7A以识别LADA中β细胞功能下降风险较高的患者。
  • TSPAN7A阳性提示需更密切监测β细胞功能变化。

局限性

  • 纵向研究样本量较小(53例LADA)。
  • 研究仅纳入东亚人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this work was to investigate whether tetraspanin 7 autoantibodies (TSPAN7A) are valuable in predicting poor beta cell function in individuals with latent autoimmune diabetes in adults (LADA). METHODS: The cross-sectional study involved participants with LADA (n = 173), type 1 diabetes (n = 158), type 2 diabetes (n = 204) and healthy control participants (n = 170). The longitudinal study involved 53 participants with LADA, with a 3-year follow-up. In both cohorts, TSPAN7A in the sera were measured by a luciferase immunoprecipitation system assay, and physical and clinical characteristics were recorded. RESULTS: The prevalence of TSPAN7A in LADA, type 1 diabetes, type 2 diabetes and healthy control participants was 21.4% (37/173), 26% (41/158), 0.5% (1/204) and 1.2% (2/170), respectively. Importantly, measurement of TSPAN7A significantly increased the number of individuals with LADA found to be positive for multiple antibodies (32.4% vs 22%; p < 0.001). Further logistic regression analysis demonstrated that positivity for TSPAN7A (OR 2.87, p = 0.034), disease duration (OR 1.83, p = 0.019) and GAD antibody titre (OR 2.67, p = 0.009) were risk factors for beta cell function in LADA, while BMI (OR 0.34, p = 0.001) was a protective factor. In the prospective study in individuals with LADA, the median annual decrease in rates of fasting C-peptide and 2 h postprandial C-peptide in individuals who were positive for TSPAN7A was significantly higher when compared with the decrease in those who were negative for TSPAN7A (34.6% vs 7.9%, p = 0.043 and 33.2% vs 11%, p = 0.041, respectively). CONCLUSIONS/INTERPRETATION: TSPAN7A are valid islet autoantibodies for use in East Asian populations with autoimmune diabetes and can discriminate individuals with LADA who have lower beta cell function after disease progression.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Shi X, Huang G, Wang Y, et al. Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA. Diabetologia. 2018. PMID: 30594957. doi:10.1007/s00125-018-4799-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。